Double-blind comparison of carbetocin versus oxytocin in prevention of uterine atony after cesarean section.

[1]  C. AbouZahr,et al.  Maternal Mortality: A Global Factbook , 1991 .

[2]  P. V. van Dongen,et al.  Ascending dose tolerance study of intramuscular carbetocin administered after normal vaginal birth. , 1998, European journal of obstetrics, gynecology, and reproductive biology.

[3]  R. Rochat,et al.  Maternal Mortality in the United States: Report From the Maternal Mortality Collaborative , 1988, Obstetrics and gynecology.

[4]  I. Mackenzie,et al.  A prospective, double-blind, randomized comparison of prophylactic intramyometrial 15-methyl prostaglandin F2 alpha, 125 micrograms, and intravenous oxytocin, 20 units, for the control of blood loss at elective cesarean section. , 1994, American journal of obstetrics and gynecology.

[5]  A. Chang,et al.  A randomised double blind comparison of Syntometrine® and Syntocinon® in the management of the third stage of labour , 1995, British journal of obstetrics and gynaecology.

[6]  W. Wassenaar,et al.  Effect of carbetocin, a long‐acting oxytocin analog on the postpartum uterus , 1992, Clinical pharmacology and therapeutics.

[7]  J. Whitehead,et al.  A FORTRAN program for the design and analysis of sequential clinical trials. , 1983, Computers and biomedical research, an international journal.

[8]  M. Ohlin,et al.  Pharmacokinetics of carbetocin, a long-acting oxytocin analogue, in nonpregnant women , 1990 .

[9]  W. Doesburg,et al.  A randomized comparison of oxytocin, sulprostone and placebo in the management of the third stage of labour , 1991 .

[10]  D. Sackett.  Bias in analytic research. , 1979, Journal of chronic diseases.

[11]  E. Royston,et al.  Preventing Maternal Deaths , 1989 .

[12]  W. Prendiville,et al.  Randomised controlled trial of oxytocin alone versus oxytocin and ergometrine in active management of third stage of labour. , 1993, BMJ.